Develops clinical-stage drug candidates and solid-form compounds for licensing to pharmaceutical and biotechnology companies.
10-K for FY2025, filed Apr 15, 2026CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., a Delaware corporation (“CDT”, “CDT Equity” or the “Company”), is a data-driven…View ↗
The Company’s pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology…View ↗
We believe that successful pre-clinical trials of the assets in our pipeline will increase the value of our assets. There is no assurance…View ↗
No revenue reported yet.
10-K for FY2025, filed Apr 15, 2026
The company expects pharmaceutical and biotechnology companies to license assets for further development and commercialization; strategic partners may handle sales, marketing and distribution.
10-K for FY2025, filed Apr 15, 2026We believe that successful pre-clinical trials of the assets in our pipeline will increase the value of our assets. There is no assurance…View ↗
To enable us to monetize our clinical assets, we, in partnership with CROs and KOLs, intend to conduct additional pre-clinical trials on…View ↗
Sales and MarketingView ↗
10-Q for Q3 FY2026, filed Nov 16, 2026
−$4.6MView ↗
8-K, filed Nov 9, 2026
On November 5, 2026, Dr. Andrew Regan, the former CEO of CDT Equity Inc. (the “Company”), delivered a letter to the Company’s Board of…View ↗
8-K, filed Sep 1, 2026
On August 31, 2026 (the “Effective Date”), CDT Equity Inc (the “Company”) appointed Mr. James Bligh to serve as Chief Executive Officer…View ↗
From blank-check search to drug development
The older report describes a blank-check company seeking a business combination, focused on real-estate and property-technology targets. The latest report describes developing clinical-stage drug assets, using solid-form chemistry and artificial intelligence, and seeking third-party licenses.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Apr 15, 2026We are a recently organized blank check company incorporated on October 19, 2021 as a Delaware corporation formed for the purpose of…View ↗
To date, our efforts have been limited to organizational activities, as well as activities related to our initial public offering and…View ↗
Our business strategy is to identify and complete our initial business combination with a company that complements the experience of our…View ↗
CDT Equity Inc., formerly Conduit Pharmaceuticals Inc., a Delaware corporation (“CDT”, “CDT Equity” or the “Company”), is a data-driven…View ↗
The Company’s pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology…View ↗
To enable us to monetize our clinical assets, we, in partnership with CROs and KOLs, intend to conduct additional pre-clinical trials on…View ↗
Loading...